Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy

被引：4

作者：

Gilbert, Lucy ^{[1
,2
,3
]}

Ramanakumar, Agnihotram, V ^{[4
]}

Festa, Maria Carolina ^{[1
,2
]}

Jardon, Kris ^{[1
,2
,3
]}

Zeng, Xing ^{[1
,2
,3
]}

Martins, Claudia ^{[1
,2
,3
]}

Shbat, Layla ^{[1
,2
]}

Alsoud, Marwa Abo ^{[1
,2
]}

Borod, Manuel ^{[3
,5
]}

Wolfson, Michael ^{[6
]}

Papaioannou, Ioanna ^{[7
]}

Basso, Olga ^{[4
,8
]}

Sampalis, John ^{[7
,9
]}

机构：

[1] McGill Univ, Gynecol Canc Serv, Hlth Ctr, Canc Care Mission, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada

[2] McGill Univ, Dept Obstet & Gynecol, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada

[3] McGill Univ, Dept Oncol, 5100 Maisonneuve Blvd West, Montreal, PQ H4A 3T2, Canada

[4] McGill Univ, Res Inst, Hlth Ctr, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada

[5] McGill Univ, Support & Palliat Care Serv, Hlth Ctr, Canc Care Mission, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada

[6] Univ Ottawa, Dept Epidemiol & Community Med, 600 Peter Morand Crescent, Ottawa, ON K1G 5Z3, Canada

[7] JSS Med Res, 9400 Henri Bourassa West, Montreal, PQ H4S 1N8, Canada

[8] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, 1020 Pine Ave West, Montreal, PQ H3A 1A2, Canada

[9] McGill Univ, Fac Med, Dept Surg, Div Surg Res, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada

来源：

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2020年 / 9卷 / 08期

关键词：

cytotoxic chemotherapy; healthcare costs; recurrent high-grade serous ovarian cancer; MAINTENANCE THERAPY; DOUBLE-BLIND; SURVIVAL; CARCINOMA; OUTCOMES; WOMEN;

D O I：

10.2217/cer-2020-0032

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Aim: To describe the direct healthcare costs associated with repeated cytotoxic chemotherapy treatments for recurrent high-grade serous cancer (HGSC) of the ovaries. Patients & methods: Retrospective review of 66 women with recurrent stage III/IV HGSC ovarian cancer treated with repeated lines of cytotoxic chemotherapy in a Canadian University Tertiary Center. Results: Mean cost of treatment of first relapse was CAD$52,227 increasing by 38% for two, and 86% for three or more relapses with median overall survival of 36.0, 50.7 and 42.8 months, respectively. In-hospital care accounted for 71% and chemotherapy drugs accounted for 17% of the total costs. Conclusion: After the third relapse of HGSC, cytotoxic chemotherapy did not prolong survival but was associated with substantially increased healthcare costs.

引用

页码：537 / 551

页数：15

共 50 条

[41] The peritoneal tumour microenvironment of high-grade serous ovarian cancer
Leinster, D. Andrew
Kulbe, Hagen
Everitt, Gemma
Thompson, Richard
Perretti, Mauro
Gavins, Felicity N. E.
Cooper, Dianne
Gould, David
Ennis, Darren P.
Lockley, Michelle
McNeish, Iain A.
Nourshargh, Sussan
Balkwill, Frances R.
JOURNAL OF PATHOLOGY, 2012, 227 (02): : 136 - 145
[42] Centrosomes - The Achilles' heel of high-grade serous ovarian cancer?
Chandrasekaran, G.
Hall, D.
Vias, M.
Brenton, J. D.
Gergely, F.
MOLECULAR BIOLOGY OF THE CELL, 2015, 26
[43] Determinants of resistance and response in high-grade serous ovarian cancer
Bowtell, David D. L.
CLINICAL CANCER RESEARCH, 2016, 22
[44] Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer
Freimund, Alison E.
Beach, Jessica A.
Christie, Elizabeth L.
Bowtell, David D. L.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2018, 32 (06) : 983 - +
[45] Evolution of platinum resistance in high-grade serous ovarian cancer
Cooke, Susanna L.
Brenton, James D.
LANCET ONCOLOGY, 2011, 12 (12): : 1169 - 1174
[46] Tumor immunogenicity status in high-grade serous ovarian cancer
Berry, Laurel
Kelly, Michael
Miller, Lance
GYNECOLOGIC ONCOLOGY, 2021, 162 : S319 - S319
[47] Novel strategies for targeting high-grade serous ovarian cancer
Perets, Ruth
Wyant, Gregory A.
Ohman, Anders W.
Setlur, Sunita R.
Crum, Christopher P.
Drapkin, Ronny
Dinulescu, Daniela M.
CLINICAL CANCER RESEARCH, 2015, 21
[48] Describing intratumoural heterogeneity in high-grade serous ovarian cancer
Nixon, K.
Wulandari, R.
Curry, E.
Rama, N.
Bowtell, D.
Cunnea, P.
Fotopoulou, C.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2019, 126 : 87 - 88
[49] Defining the Molecular Footsteps of High-Grade Serous Ovarian Cancer
Nagendra, P.
Lombard, J.
Jamaluddin, F.
Tanwar, P.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 26 - 26
[50] Principles of dormancy evident in high-grade serous ovarian cancer
Shepherd, Trevor G.
Dick, Frederick A.
CELL DIVISION, 2022, 17 (01)

← 1 2 3 4 5 →